Description

D-Pimobendan is a high-purity, enantiomerically pure pharmaceutical intermediate and active pharmaceutical ingredient (API). This compound is a calcium sensitizer and phosphodiesterase III inhibitor, making it a critical component in advanced cardiovascular research and drug development. It is essential for manufacturers and research institutions focused on developing and producing innovative treatments for congestive heart failure in veterinary and potential human therapeutic applications.

Application

• Pharmaceutical API Synthesis: Primary use as the active enantiomer in the manufacture of pimobendan-based veterinary cardiology drugs.
• Veterinary Medicine Production: Key ingredient in formulated products for the management of congestive heart failure (CHF) in dogs, specifically for dilated cardiomyopathy (DCM) and mitral valve disease (MVD).
• Cardiovascular Research: A vital reference standard and tool compound for studying calcium sensitization mechanisms and inotropic agents in preclinical research.
• Process Development & Scale-up: Serves as a critical intermediate for chemical process optimization and GMP-scale manufacturing campaigns.
• Analytical Standard: Used as a certified reference material (CRM) for quality control testing, method validation, and regulatory submissions.
• New Chemical Entity (NCE) Development: Explored in research for potential human therapeutic applications targeting heart failure.

Basic Information

Product Name	D-Pimobendan
CAS No.	118428-38-9
Molecular Formula	C19H18N4O2
Molecular Weight	334.37 g/mol
Synonyms	(+)-Pimobendan; (R)-(+)-Pimobendan; (4R)-4,5-Dihydro-6-[2-(4-methoxyphenyl)-1H-benzimidazol-5-yl]-5-methyl-3(2H)-pyridazinone; UD-CG 212; Pimobendan enantiomer; Vetmedin (brand name reference); Benzimidazole-pyridazinone derivative; 6-[2-(p-Methoxyphenyl)-1H-benzimidazol-5-yl]-5-methyl-4,5-dihydro-3(2H)-pyridazinone, (R)-
EINECS	Contact for details

Quality Control

Our D-Pimobendan is manufactured under strict quality management systems. Each batch is subjected to comprehensive analytical testing, including chiral purity verification, to ensure it meets stringent specifications for pharmaceutical use. Certificates of Analysis (COA) detailing identity, purity, and impurity profiles are provided and can be tailored to support GMP, ICH Q7, and regulatory filing requirements.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at controlled room temperature (15-25°C). The product is light-sensitive and should be handled under appropriate conditions to maintain stability.

Specification

Item	Specification
Appearance	White to off-white crystalline powder
Identification (IR)	Conforms to reference spectrum
Identification (HPLC)	Retention time corresponds to reference standard
Assay (HPLC)	≥98.5%
Chiral Purity (Enantiomeric Excess)	≥99.0%
Related Substances (HPLC)	Individual impurity ≤0.5%; Total impurities ≤1.5%
Residual Solvents (GC)	Complies with ICH Q3C guidelines
Loss on Drying	≤0.5%
Heavy Metals	≤20 ppm

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.